Suppr超能文献

将与泰-萨克斯病B1变异型相关的α亚基突变引入β亚基,会产生一种没有催化活性的β-己糖胺酶B。

Introduction of the alpha subunit mutation associated with the B1 variant of Tay-Sachs disease into the beta subunit produces a beta-hexosaminidase B without catalytic activity.

作者信息

Brown C A, Neote K, Leung A, Gravel R A, Mahuran D J

机构信息

Research Institute, Hospital for Sick Children, Toronto, Ontario, Canada.

出版信息

J Biol Chem. 1989 Dec 25;264(36):21705-10.

PMID:2532211
Abstract

Lysosomal beta-hexosaminidase (beta-N-acetylhexosaminidase, EC 3.2.1.52) occurs in two major isozyme forms, hexosaminidase A (alpha beta) and hexosaminidase B (beta beta). Although dimer formation is required for enzymatic activity, both subunits contain active sites which share many common substrates. However, the alpha subunit alone confers on hexosaminidase A the specificity for negatively charged substrates, e.g. GM2 ganglioside. Recently, a point mutation, producing a single amino acid substitution in the alpha subunit (Arg178-His), has been found to be associated with the B1 variant phenotype of Tay-Sachs disease (Ohno, K., and Suzuki, K. (1988) J. Neurochem. 50, 316-318). This variant is characterized by normal levels of hexosaminidase A as measured by a common artificial substrate, but an absence of activity toward alpha subunit-specific substrates. However, because of the presence of an active beta subunit in the mutant hexosaminidase A, it has not been possible to determine whether the affected alpha subunit has undergone a change in substrate specificity or become totally inactive. In order to define the full effect of the B1 mutation we have taken advantage of the common evolutionary origin of the genes coding for the alpha and beta subunits. Since the B1 mutation occurs in a region of extended identity between the two subunits, we have duplicated the Arg178-His mutation in a cDNA coding for the human beta subunit (Arg211-His). By expression of the mutant construct in monkey COS cells we have been able to examine the effect of this mutation on beta subunits which are capable of forming stable, active homodimers, an experiment that could not readily be accomplished with heterodimeric hexosaminidase A. Our data show that beta homodimers containing the Arg211-His substitution are formed and are transported into the lysosome in a manner identical to that of normal pro-hexosaminidase B. However, the mutant homodimers are processed at a slower rate and are less stable in the lysozyme. Their most striking feature was a total lack of normal hexosaminidase B activity. We conclude that while the effect of the Arg178-His substitution is not strictly limited to the active site, the severe B1 phenotype results from a totally inactive alpha-subunit in hexosaminidase A.

摘要

溶酶体β - 氨基己糖苷酶(β - N - 乙酰氨基己糖苷酶,EC 3.2.1.52)以两种主要同工酶形式存在,即氨基己糖苷酶A(αβ)和氨基己糖苷酶B(ββ)。虽然酶活性需要形成二聚体,但两个亚基都含有共享许多共同底物的活性位点。然而,单独的α亚基赋予氨基己糖苷酶A对带负电荷底物(如GM2神经节苷脂)的特异性。最近,已发现一个点突变,该突变在α亚基中产生单个氨基酸取代(Arg178 - His),与泰 - 萨克斯病的B1变异表型相关(Ohno, K., and Suzuki, K. (1988) J. Neurochem. 50, 316 - 318)。通过一种常见的人工底物测量,该变异的特征是氨基己糖苷酶A水平正常,但对α亚基特异性底物缺乏活性。然而,由于突变的氨基己糖苷酶A中存在活性β亚基,所以无法确定受影响的α亚基是底物特异性发生了变化还是完全失活。为了确定B1突变的全面影响,我们利用了编码α和β亚基的基因的共同进化起源。由于B1突变发生在两个亚基之间具有延伸一致性的区域,我们在编码人β亚基(Arg211 - His)的cDNA中复制了Arg178 - His突变。通过在猴COS细胞中表达突变构建体,我们能够研究该突变对能够形成稳定、活性同型二聚体的β亚基的影响,而用异源二聚体氨基己糖苷酶A则不容易完成这样的实验。我们的数据表明,含有Arg211 - His取代的β同型二聚体形成,并以与正常前体氨基己糖苷酶B相同的方式转运到溶酶体中。然而,突变的同型二聚体加工速度较慢,在溶酶体中稳定性较差。它们最显著的特征是完全缺乏正常的氨基己糖苷酶B活性。我们得出结论,虽然Arg178 - His取代的影响并不严格局限于活性位点,但严重的B1表型是由氨基己糖苷酶A中完全失活的α亚基导致的。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验